<DOC>
	<DOCNO>NCT00088595</DOCNO>
	<brief_summary>Study evaluate SOM230 patient metastatic carcinoid tumor</brief_summary>
	<brief_title>Study Evaluating SOM230 Patients With Metastatic Carcinoid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<criteria>Patients biopsyproven metastatic carcinoid tumor Patients least one measurable lesion ( exclude bone ) Patients must consider inadequately control Sandostatin LAR therapy base symptom carcinoid syndrome ( diarrhea and/or flush ) define experience minimum average least four bowel movement per day minimum average least two episode flush per day Patients previously treat certain medication may require without certain medication prior enter study Patients undergone major recent surgery / surgical therapy cause within 1 month Patients cytotoxic chemotherapy interferon therapy within last 2 month Patients uncontrolled diabetes mellitus Patients receive radiotherapy reason within last 4 week must recover side effect radiotherapy Patients congestive heart failure unstable angina , cardiac arrhythmia history acute myocardial infarction within three month precede enrollment Patients chronic liver disease Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control . History immunocompromise , include positive HIV test result Patients history alcohol drug abuse 6 month period prior receive SOM230 Patients give blood donation ( 400 mL ) within 2 month receive SOM230 Patients participate clinical investigation investigational drug within 1 month prior dose Patients additional active malignant disease within last five year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>SOM230</keyword>
	<keyword>Sandostatin</keyword>
	<keyword>Carcinoid syndrome</keyword>
</DOC>